Adenocarcinoma of Lung

12 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Adenocarcinoma of Lung
Treatment and conditionWhere it standsTrials
Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pulmonary segmentectomy for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Segmentectomy for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sotorasib for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1